Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw strong trading volume on Friday . 5,255 shares traded hands during trading, an increase of 88% from the previous session’s volume of 2,795 shares.The stock last traded at $50.51 and had previously closed at $50.00.

Analysts Set New Price Targets

Several research analysts have weighed in on ZLDPF shares. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Zacks Research lowered Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 13th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wolfe Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zealand Pharma A/S has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average is $46.26 and its 200 day moving average is $48.85. The company has a market cap of $3.61 billion, a P/E ratio of 8.38 and a beta of 0.88.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.